Equivalence by Design for Advanced Dosage Forms and Drug Products - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Equivalence by Design for Advanced Dosage Forms and Drug Products
FDA has been encouraging drug sponsors to use a systematic approach such as quality-by-design principles for pharmaceutical development.

Pharmaceutical Technology
Volume 33, Issue 10, pp. 104-110

An alternative approach to assessing bioequivalence

Given the assumption of constant clearance, which is generally true within each individual across different formulations of the same drug substance, it has been recognized that bioequivalence should be assessed by focusing on the comparison of absorption pattern rather than distribution, metabolism, or elimination process of the drug. This recommendation is preferred because the absorptive process is more sensitive to a difference between formulations as compared with other biological events occurring subsequent to drug absorption. It follows that because absorption is mainly controlled by when, where, and how a drug is released from a formulation, an alternative approach for the assessment of bioequivalence may be directed to the comparison of in vivo drug delivery profiles (iDDPs) before the drug is absorbed (8). In doing so, equivalence in the rate and extent of drug absorption may be established by showing the similarity of iDDPs between products in comparison.

Schematically, from the entry of a formulation into the body to the point at which the drug reaches systemic circulation or the site of action, an iDDP may consist of some or all of the following steps: deposition, transit, retention, release, and transport. In this setting, the relative contribution of each step to an iDDP may depend on the dosage form, drug product, route of administration, or clinical indication under consideration. For example, various dosage forms are made with distinct objectives that can be manifested in their iDDPs. Where the drug is deposited will be an important point for nasal sprays and aerosols, as well as locally acting GI products and dermatological medications. In contrast, maneuvering drug transit through the GI tract is the primary goal in the design of orally administered extended-release products. Although control of retention time in the stomach is essential for floating systems, the location of drug release in the intestine is the focus for delayed-release dosage forms (e.g., enteric-coated tablets). On the other hand, consideration of transport process is crucial for achieving bioequivalence of liposomal products and other similar lipid-based formulations, given the unique characteristics of these dosage forms.

Equivalence by design

From product design and manufacturing perspectives, bioequivalence can be advanced by matching the iDDP of the reference product during test-product development, which is particularly important for complex pharmaceutical dosage forms and delivery systems. Technically, this objective can be achieved using an approach analogous to the quality-by-design (QbD) paradigm that the ICH and FDA are currently promoting for pharmaceutical development (9). As illustrated in the FDA Q8(R1) guidance, the application of a QbD approach must begin with predefined objectives; namely, a quality target product profile as related to quality, safety, and efficacy (9). After the quality target product profile is defined, one will identify critical quality attributes of the product and use these attributes as the benchmark to design formulation and manufacturing process. In parallel with the QbD concept, an equivalence-by-design (EbD) approach can start with determining the target (or reference) product profile based on the critical steps of its iDDP as related to bioequivalence. Once the target (reference) iDDP is defined, one may identify biomarkers or in vitro markers to characterize critical steps of the target (reference) iDDP. The test formulation and manufacturing process can then be designed with the use of these markers to match the target iDDP.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here